Literature DB >> 27004213

Significance of IASLC/ATS/ERS classification for early-stage lung adenocarcinoma patients in predicting benefit from adjuvant chemotherapy.

Yusuke Takahashi1, Takashi Eguchi1, Sarina Bains1, Prasad S Adusumilli1.   

Abstract

Entities:  

Year:  2016        PMID： 27004213      PMCID： PMC4779772          DOI： 10.3978/j.issn.2305-5839.2015.10.40

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  23 in total

1.  Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

Authors:  Gary M Strauss; James E Herndon; Michael A Maddaus; David W Johnstone; Elizabeth A Johnson; David H Harpole; Heidi H Gillenwater; Dorothy M Watson; David J Sugarbaker; Richard L Schilsky; Everett E Vokes; Mark R Green
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

Review 2.  Non-small-cell lung cancer.

Authors:  Peter Goldstraw; David Ball; James R Jett; Thierry Le Chevalier; Eric Lim; Andrew G Nicholson; Frances A Shepherd
Journal:  Lancet       Date:  2011-05-10       Impact factor: 79.321

Review 3.  Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer.

Authors:  Szabolcs Modok; Howard R Mellor; Richard Callaghan
Journal:  Curr Opin Pharmacol       Date:  2006-05-11       Impact factor: 5.547

Review 4.  Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC.

Authors:  Alex Chang
Journal:  Lung Cancer       Date:  2010-10-16       Impact factor: 5.705

5.  Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection.

Authors:  Ming-Sound Tsao; Sophie Marguet; Gwénaël Le Teuff; Sylvie Lantuejoul; Frances A Shepherd; Lesley Seymour; Robert Kratzke; Stephen L Graziano; Helmut H Popper; Rafael Rosell; Jean-Yves Douillard; Thierry Le-Chevalier; Jean-Pierre Pignon; Jean-Charles Soria; Elisabeth M Brambilla
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

6.  Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification on death and recurrence in completely resected stage I lung adenocarcinoma.

Authors:  Jung-Jyh Hung; Wen-Juei Jeng; Teh-Ying Chou; Wen-Hu Hsu; Kou-Juey Wu; Biing-Shiun Huang; Yu-Chung Wu
Journal:  Ann Surg       Date:  2013-12       Impact factor: 12.969

Review 7.  New pathologic classification of lung cancer: relevance for clinical practice and clinical trials.

Authors:  William D Travis; Elisabeth Brambilla; Gregory J Riely
Journal:  J Clin Oncol       Date:  2013-02-11       Impact factor: 44.544

8.  Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival.

Authors:  Hideki Ujiie; Kyuichi Kadota; Jamie E Chaft; Daniel Buitrago; Camelia S Sima; Ming-Ching Lee; James Huang; William D Travis; Nabil P Rizk; Charles M Rudin; David R Jones; Prasad S Adusumilli
Journal:  J Clin Oncol       Date:  2015-08-10       Impact factor: 44.544

Review 9.  Management of non-small-cell lung cancer: recent developments.

Authors:  Martin Reck; David F Heigener; Tony Mok; Jean-Charles Soria; Klaus F Rabe
Journal:  Lancet       Date:  2013-08-24       Impact factor: 79.321

10.  The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma.

Authors:  Yang Zhang; Jing Li; Rui Wang; Yuan Li; Yunjian Pan; Deng Cai; Haichuan Hu; Hang Li; Ting Ye; Xiaoyang Luo; Yiliang Zhang; Bin Li; Lei Shen; Yihua Sun; Haiquan Chen
Journal:  Sci Rep       Date:  2014-11-24       Impact factor: 4.379
View more
  1 in total

1.  Prognostic and predictive value of the novel classification of lung adenocarcinoma in patients with stage IB.

Authors:  Jizhuang Luo; Qingyuan Huang; Rui Wang; Baohui Han; Jie Zhang; Heng Zhao; Wentao Fang; Qingquan Luo; Jun Yang; Yunhai Yang; Lei Zhu; Tianxiang Chen; Xinghua Cheng; Yiyang Wang; Jiajie Zheng; Han Wu; Weicong Xia; Haiquan Chen
Journal:  J Cancer Res Clin Oncol       Date:  2016-07-05       Impact factor: 4.553
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.